<DOC>
	<DOCNO>NCT00411905</DOCNO>
	<brief_summary>We evaluate efficacy association Low dose Cytarabine association Bortezomib treatment patient diagnose high risk Myelodysplastic syndrome . Our aim decrease transfusion requirement possible induce complete least partial remission .</brief_summary>
	<brief_title>Bortezomib Low Dose Cytarabine Treatment High-Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>Four cycle treatment propose 28 day interval ambulatory set Cycle 1 : - Cytarabine 10 mg /m2/day subcutaneous injection 14 day - Bortézomib 1,5mg/m2 day 1,4,8,11 Cycles 2 , 3 , 4 : - Cytarabine 20 mg /m2/j subcutaneous injection 14 day - Bortézomib 1,5mg/m2 day 1,4,8,11 Bone marrow aspirate evaluate first cycle , second fourth cycle Responding patient may continue treatment 2 cycle</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>MDS IPSS score Int2 High Life expectancy great 6 month No available treatment option MDS IPSS score Low Int1 &gt; 30 % bone marrow blast clinical neuropathy great grade 2 ECOG Score 3 4 Creatinine clearance &lt; 30 ml/min LMMC Pregnant patient lactate mother Patients receive intensive chemotherapy 3 month prior inclusion Patients uncontrolled pulmonary , cardiac , neurological , gastrointestinal genitourinary disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>IPSS Int-2 High risk</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Low dose Cytarabine</keyword>
	<keyword>Bone Marrow disease</keyword>
</DOC>